Flex Pharma, Inc (FLKS) saw its loss almost stable for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $7.89 million, or $0.51 a share.
Revenues for the quarter were $0.30 million. The company has not recorded any revenues for the previous year period. Gross margin for the quarter was at 55.18 percent.
Operating loss for the quarter was $7.98 million, compared with an operating loss of $7.93 million in the previous year period.
"When we initiate our Phase 2 clinical studies in ALS and CMT later this year, FLX-787 will be amongst the most advanced, novel clinical compounds in development for these conditions," stated Christoph Westphal, M.D., Ph.D., Chair and chief execuitve officer of Flex Pharma. “With over $61 million in cash and investments at year end, Flex is well funded through early 2019 to execute upon our value-creating objectives."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
